HYBRIGENICS : Hybrigenics' first half 2012 revenues of EUR 2 million at the same level as in 2011

Press Release

Hybrigenics' first half 2012 revenues of EUR 2 million are at the same level as in 2011

Paris, 18 July 2012 - Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, today announces its revenues and cash position for the first half of 2012.

EUR

(million)

1st Half

2012

1st Half

2011

Change

%

Turnover from scientific activities 1.62 1.61 +0.6%

Other revenues 0.38 0.43 -11.6%

Total revenues 2.00 2.04 -2%

Cash position (end of period) 4.16 1.90 +119%

Hybrigenics total revenues for H1 2012 remained stable at about €2 million. A slight decrease of

5% in revenues from protein interactions services (turnover and grants of €1.40 million vs.

€1.48 million) was compensated by the increase of 25% in turnover from the research collaboration with Servier (€0.375 million vs. €0.3 million).

Hybrigenics' cash position on June 30th, 2012 amounted to €4.2 million compared to

€2.7 million on December 31st, 2011, and €1.9 million on June 30th, 2011. During H1 2012, a total of €3.8 million has been raised: €3.3 million from two consecutive PIPEs in March and €0.5

million earlier in the year from drawings on the equity line agreement with the American fund

Yorkville Global Advisors; €8.2 million are still available on this line.

"The revenues generated by our research and services activities showed a remarkable resistance to the tough economic environment for outsourcing or public funding of basic research," said Remi Delansorne, Hybrigenics' CEO. "Our cash position is at its highest level since the end of 2007, just after the IPO. These funds allow us to finance as planned the clinical trial of inecalcitol in chronic lymphocytic leukemia".

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE- Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the

first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

1/2

Press Release

***

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG

Hybrigenics Rémi Delansorne CEO

Tel.: [phone] [e-mail]

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent Tel.: [phone] [e-mail]

2/2